News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
STAMFORD, Conn. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the
View HTML
Toggle Summary Cara Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Announces Equity Grants to Employees Under Inducement Plan
STAMFORD, Conn. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the
View HTML
Toggle Summary Cara Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
STAMFORD, Conn. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Announces Positive Topline Data From Phase 2 Trial of Oral KORSUVA™ in Chronic Kidney Disease Patients with Moderate-to-Severe Pruritus
– Met primary endpoint with statistically significant reduction in mean worst itching intensity NRS scores with 1 mg tablet strength vs. placebo after 12-week treatment period (p=0.018) – –  Oral KORSUVA™ well-tolerated after 12 weeks of treatment – –  Conference call today at 8:30 a.m.
View HTML
Toggle Summary Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced company
View HTML
Toggle Summary Cara Therapeutics Announces Publication of Difelikefalin (KORSUVA™ Injection) KALM™-1 Phase 3 Trial Results in the New England Journal of Medicine
- Treatment with KORSUVA Injection resulted in statistically significant reduction in pruritus intensity and improvement in itch-related quality of life measures vs placebo for both primary and secondary endpoints - STAMFORD, Conn. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
View HTML
Toggle Summary Cara Therapeutics Reports Third Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa
View HTML
Toggle Summary Cara Therapeutics Announces Presentations at Kidney Week 2019
Late-breaking oral presentation to highlight data from KALM-1 pivotal Phase 3 trial of KORSUVA™ Injection in hemodialysis patients with pruritus STAMFORD, Conn. , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and
View HTML
Toggle Summary Cara Therapeutics to Announce Third Quarter 2019 Financial Results on November 5, 2019
STAMFORD, Conn. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the
View HTML